首页> 美国卫生研究院文献>Springer Open Choice >The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter single-arm phase II trial (CCOG-0801)

【2h】

The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter single-arm phase II trial (CCOG-0801)

机译：贝伐单抗在一线mFOLFOX6继之以二线FOLFIRI治疗晚期结直肠癌的患者中超过一级进展的疗效和安全性：一项多中心单臂II期试验（CCOG-0801）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PurposeThe aim of this study was to evaluate the efficacy and safety of the planned continuation of bevacizumab beyond first progression (BBP) in Japanese patients with metastatic colorectal cancer (mCRC).

机译：目的本研究的目的是评估在日本转移性结直肠癌（mCRC）患者中，贝伐单抗计划超越首次进展（BBP）继续进行的疗效和安全性。

著录项

期刊名称 Springer Open Choice
作者
Goro Nakayama; Keisuke Uehara; Kiyoshi Ishigure; Hiroyuki Yokoyama; Akiharu Ishiyama; Takehiko Eguchi; Kenji Tsuboi; Norifumi Ohashi; Tsutomu Fujii; Hiroyuki Sugimoto; Masahiko Koike; Michitaka Fujiwara; Yuich Ando; Yasuhiro Kodera;
展开▼
作者单位

展开▼
年(卷),期 -1(70),4
年度 -1
页码 575–581
总页数 7
原文格式 PDF
正文语种
中图分类外科学;
关键词
Colorectal cancer Chemotherapy Bevacizumab beyond progression (BBP);

机译：大肠癌;化学疗法;贝伐单抗超越病程（BBP）;

相似文献

外文文献
中文文献

1. The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: A multicenter, single-arm, phase II trial (CCOG-0801) [J] . NakayamaG., UeharaK., IshigureK., Cancer chemotherapy and pharmacology. . 2012,第4期

机译：贝伐单抗在一线mFOLFOX6继之以二线FOLFIRI治疗晚期结直肠癌的患者中超过首次进展的疗效和安全性：一项多中心，单臂，II期试验（CCOG-0801）
2. The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801) [J] . Goro Nakayama, Keisuke Uehara, Kiyoshi Ishigure, Cancer Chemotherapy and Pharmacology . 2012,第4期

机译：贝伐单抗在一线mFOLFOX6继之以二线FOLFIRI治疗晚期结直肠癌的患者中，超过一级进展的疗效和安全性：一项多中心，单臂，II期试验（CCOG-0801）
3. Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801) [J] . Miwa Keisuke, Oki Eiji, Emi Yasunori, International journal of clinical oncology . 2016,第1期

机译：由转移性结直肠癌患者组成的一线mFOLFOX6加贝伐单抗和FOLFIRI加贝伐单抗组成的交替方案的II期临床试验：FIREFOX加贝伐单抗试验（KSCC0801）
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Efficacy and safety of novel collagen conduits filled with collagen filaments to treat patients with peripheral nerve injury: A multicenter, controlled, open-label clinical trial [D] . Saeki Masaomi, 佐伯将臣 2019

机译：充满胶原细丝的新型胶原蛋白导管治疗周围神经损伤患者的疗效和安全性：一项多中心，对照，开放标签的临床试验
6. A multicenter single-arm Phase II clinical trial of second-line FOLFIRI plus panitumumab after first-line treatment with FOLFOX plus panitumumab for initial RAS wild-type colorectal cancer with evaluation of circulating tumor DNA: A protocol study [O] . Hiromichi Maeda, Naoki Nagata, Takeshi Nagasaka, -1

机译：方案研究：二线FOLFIRI加帕尼单抗一线治疗后用FOLFOX加帕尼单抗一线治疗初始RAS野生型结直肠癌的多中心单臂II期临床试验：方案研究
7. The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801) [O] . Goro Nakayama, Keisuke Uehara, Kiyoshi Ishigure, 2012

机译：贝伐单抗在一线mFOLFOX6继之以二线FOLFIRI治疗晚期结直肠癌的患者中，超过一级进展的疗效和安全性：一项多中心，单臂，II期试验（CCOG-0801）

The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter single-arm phase II trial (CCOG-0801)

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅